Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study

share with twitter share with LinkedIn share with facebook
09/18/2020 | 06:05pm EDT

NEW YORK, Sept 18 (Reuters) - Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday.

The drug combination also doubled patients' median length of time before their cancer began to worsen to 16.6 months compared to progression-free survival of 8.3 months for patients treated with the chemotherapy sunitinib, an older Pfizer Inc drug sold under the brand name Sutent.

"There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston.

He noted that the oncology community is already familiar with both drugs and that the combination demonstrated positive results on all the study's goals.

The Phase III study of 651 patients with advanced or metastatic renal cell carcinoma was being presented as part of the European Society for Medical Oncology meeting being held virtually this year. A brief summary of the data, known as an abstract, was released on Friday.

Researchers said the safety of the combination was manageable and consistent with the side effect profile of the two drugs when used individually.

Opdivo is one of Bristol’s top-selling drugs, with analysts forecasting nearly $7 billion in sales this year.

The new data could help boost sales that have slowed in recent years as Opdivo was eclipsed by Merck & Co’s rival drug Keytruda. (Reporting by Michael Erman Editing by Bill Berkrot)


Stocks mentioned in the article
ChangeLast1st jan.
EXELIXIS, INC. 2.11% 22.29 Delayed Quote.26.50%
PFIZER INC. 2.00% 38.18 Delayed Quote.-2.55%
PFIZER LIMITED 1.00% 5112.85 End-of-day quote.21.04%
share with twitter share with LinkedIn share with facebook
All news about EXELIXIS, INC.
10:25aEXELIXIS : to Release Third Quarter 2020 Financial Results on Thursday, November..
AQ
10/22EXELIXIS : to Release Third Quarter 2020 Financial Results on Thursday, November..
BU
10/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
AQ
10/19BRISTOL MYERS SQUIBB : Exelixis Get Priority Review for Kidney-Cancer Treatment
DJ
10/12EXELIXIS : to Present the Preclinical Profile and Initial Clinical Pharmacokinet..
AQ
10/12EXELIXIS : and Aurigene Announce That Promising Preclinical Data to Be Presented..
AQ
10/09EXELIXIS : and Aurigene Announce That Promising Preclinical Data to Be Presented..
BU
10/09EXELIXIS : to Present the Preclinical Profile and Initial Clinical Pharmacokinet..
BU
09/22EXELIXIS : Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC..
AQ
09/21BRISTOL MYERS SQUIBB : Opdivo in Combination with CABOMETYX Demonstrates Signifi..
AQ
More news
Financials (USD)
Sales 2020 925 M - -
Net income 2020 130 M - -
Net cash 2020 1 313 M - -
P/E ratio 2020 55,9x
Yield 2020 -
Capitalization 6 888 M 6 888 M -
EV / Sales 2020 6,03x
EV / Sales 2021 4,57x
Nbr of Employees 617
Free-Float 98,5%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 30,96 $
Last Close Price 22,29 $
Spread / Highest target 79,5%
Spread / Average Target 38,9%
Spread / Lowest Target 12,2%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.23.89%6 745
GILEAD SCIENCES, INC.-6.63%76 063
REGENERON PHARMACEUTICALS53.33%60 584
VERTEX PHARMACEUTICALS-4.05%54 719
WUXI APPTEC CO., LTD.58.33%39 347
BEIGENE, LTD.83.27%27 531